Alvotech (ALVO) news

Alvotech's AVT80 license application accepted for FDA review

Alvotech SA: BofA Global Research initiates coverage with buy rating; price objective $7

BofA Global Research has initiated coverage of Alvotech SA (ALVO) with a "Buy" rating and a price objective of $7 per share, citing the company's strategic positioning in the biosimilars sector and its pipeline of late-stage candidates [1]. The firm highlighted Alvotech's focus on developing…

Alvotech: Pact has value up to ~$150M in upfront, other payments

Alvotech has entered into a partnership agreement that includes payments totaling approximately $150 million . The agreement, which was finalized in the first half of 2026, is part of the company’s broader strategy to support ongoing pipeline development . The upfront payment component of the deal…

Alvotech: Pact covers two of its drug candidates in US, Asia

Alvotech has reached a licensing and settlement agreement with Regeneron and Bayer, resolving all remaining patent disputes related to its biosimilar to Eylea® (aflibercept) in markets outside the United States. The agreement grants Alvotech the right to manufacture and supply its aflibercept…

Alvotech: Licensing, commercialization pact with Lotus Pharmaceutical for proposed biosimilars to Durvalumab

Alvotech (NASDAQ: ALVO) has entered into a licensing and commercialization agreement with Lotus Pharmaceutical Co., Ltd. for the development and commercialization of proposed biosimilars to Durvalumab, a PD-L1 inhibitor used in the treatment of various cancers. Under the terms of the agreement,…